Nasdaq exas.

127.60%. Get the latest Exact Sciences Corp (EXAS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment..."Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the average one-year price target for Exact Sciences is 77.82. The forecasts range from a low of 55.55 to a high of $99.75. The ...Direct. 3,000. $16.52. 42,830. Back to EXAS Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC ...Exact Sciences Corp (NASDAQ:EXAS) Exact Sciences Corp. 65.13. Delayed Data. As of Nov 21. -2.15 / -3.20%. Today’s Change. 40.73.Web

Enter your email address below to receive the latest news and earnings results for EXAS and its competitors with MarketBeat's FREE daily newsletter. EXAS …WebAt Stock Options Channel, our YieldBoost formula has looked up and down the EXAS options chain for the new July 8th contracts and identified one put and one call contract of particular interest ...

Find the latest on option chains for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Exact Sciences Corp (EXAS) latest news, insider trading and hedge fund ownership data provided by Insider Monkey. ... Exact Sciences Corporation (NASDAQ:EXAS) Q3 2023 Earnings Call Transcript.

Exact Sciences (EXAS) closed the most recent trading day at $60.68, moving -0.49% from the previous trading session. This change was narrower than the S&P 500's daily loss of 2.77%. Meanwhile, the ...Among the largest underlying components of ARKG, in trading today EXACT Sciences Corp. (Symbol: EXAS) is down about 0.3%, Ionis Pharmaceuticals Inc (Symbol: IONS) is up about 3%, and Intellia ...Aug 28, 2023 · One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -16.81%, and its shares gained 127.30% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ... Exact Sciences (NASDAQ:EXAS) produces and sells diagnostic and cancer screening tests. The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ...

Exact Sciences Corp ( NASDAQ:EXAS) is working on the development of additional tests, with the goal of bringing new, innovative cancer tests to patients worldwide. The company has reported a net ...

On March 9, 2023, Citigroup upgraded their outlook for EXACT Sciences (NASDAQ:EXAS) from Neutral to Buy.. Analyst Price Forecast Suggests 15.57% Upside. As of March 9, 2023, the average one-year ...

Exact Sciences Co. (NASDAQ:EXAS – Free Report) – Equities researchers at William Blair increased their FY2023 earnings per share (EPS) estimates for Exact Sciences in a report released on ...MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23 ...On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...Exact Sciences (NASDAQ:EXAS) is a leading international company specialized in advanced cancer diagnostics. ... To EXAS's credit, this debt issuance has been opportunistic CV offerings, at ...MADISON, Wis., Nov. 3, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $523 million for the third quarter ended September 30, 2022, compared to $456 million for the same period of 2021.Feb 10, 2023 · As of February 10, 2023, the average one-year price target for EXACT Sciences is $66.64. The forecasts range from a low of $35.35 to a high of $99.75. The average price target represents an ... EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after ...Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis. Exact Sciences Corporation Common Stock (EXAS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.WebEXACT Sciences Corporation (NASDAQ:EXAS) Number of Hedge Fund Holders: 28. Exact Sciences Corporation (NASDAQ:EXAS) is a leading global provider of cancer screening and diagnostic test products ...17 Nov 2023 ... PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has ...

The last time Exact Sciences (NASDAQ: EXAS) announced its quarterly results, revenue increased 64% compared with the prior-year period. It was a different story on the company's bottom line ...A market research report on Exact Sciences ( NASDAQ: EXAS) from Cathie Wood's ARK-Invest ( ARKK) ( ARKG) has caught a lot of attention with another assertive call on the share price performance in ...

At Stock Options Channel, our YieldBoost formula has looked up and down the EXAS options chain for the new August 26th contracts and identified one put and one call contract of particular interest ...View Our Latest Research Report on EXAS. Exact Sciences Price Performance. Shares of NASDAQ EXAS opened at $67.29 on Tuesday. The stock has a market capitalization of $12.17 billion, a price-to ...Nov 1, 2023 · Exact Sciences Corp (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, announced on November 1, 2023, that the company generated revenue of $628.3 million for the third ... TSLA. Tesla, Inc. Common Stock. $207.30 +1.54 +0.75%. Find the latest dividend history for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.9 Okt 2023 ... (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third ...17 Nov 2023 ... PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has ...

Exact Sciences (NASDAQ:EXAS) is a leading international company specialized in advanced cancer diagnostics. Renowned for its development of impactful cancer diagnostic tests, ...

MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23 ...

Exact Sciences Corporation EXAS continues to make significant progress with its Cologuard test. However, the pandemic-led continued business disruption is a concern. Exact Sciences currently ...Fintel reports that on May 10, 2023, Credit Suisse maintained coverage of Exact Sciences (NASDAQ:EXAS) with a Neutral recommendation.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24 ...EXACT Sciences Corporation stock price (EXAS) NASDAQ: EXAS. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert EXACT Sciences Corporation stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.To find the current corn price per bushel, there are a number of websites and places to look for predictions about the commodities market. Corn prices are listed on sites like NASDAQ and AgWeb if you want a quick answer.Nov 30, 2023Find the latest Earnings Report Date for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.The latest price target for Exact Sciences ( NASDAQ: EXAS) was reported by Goldman Sachs on Friday, November 3, 2023. The analyst firm set a price target for 90.00 expecting EXAS to rise to within ... Nov 17, 2023 · Close $61.17 Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is willing to buy or sell a stock. The bid is the highest amount that a buyer is currently willing... Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt Oct 04. Price target increased by 7.0% to US$109 Sep 19. Exact Sciences Corporation (NasdaqCM:EXAS) agreed to acquire Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A). Sep 13. Executive VP & CFO notifies of intention to sell stock

The latest price target for . Exact Sciences (NASDAQ: EXAS) was reported by Goldman Sachs on November 3, 2023.The analyst firm set a price target for $90.00 expecting EXAS to rise to within 12 ...At Stock Options Channel, our YieldBoost formula has looked up and down the EXAS options chain for the new October 28th contracts and identified one put and one call contract of particular ...On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...2 Nov 2023 ... ... Nasdaq MarketSIte · Trust Center · Newsletters · Chrome Extension · Privacy Policy · Cookies · Legal; Cookies Settings. © 2023, Nasdaq, Inc. All ...Instagram:https://instagram. chpt stockstrading the spyfidelity blue chip growth etfphpusd Exact Sciences EXAS Operating Losses;.Another 70% to Fall!! The EXAC chart has been a downtrend from $130 to $40 with a High VOLUME. The stock is making new bottoms while insiders and the executive team have constantly been selling at any price! The stock is down 70% from its high of $137! insidertradesamam stock Turning to the calls side of the option chain, the call contract at the $60.00 strike price has a current bid of $4.20. If an investor was to purchase shares of EXAS stock at the current price ... day trading courses in person Find the latest SEC Filings data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.According to the issued ratings of 16 analysts in the last year, the consensus rating for Exact Sciences stock is Moderate Buy based on the current 4 hold ratings and 12 buy ratings for EXAS. The average twelve-month price prediction for Exact Sciences is $96.56 with a high price target of $130.00 and a low price target of $73.00.